RevMed’s pancreatic cancer drug inches closer to EU approval after panel’s backing - Pharmaceutical Technology

Revolution’s Rasonque has been called a turning point for pancreatic cancer patients, nearly doubling median overall survival in the second-line setting. Revolution’s Rasonque has been called a turning point for pancreatic cancer patients, nearly doubling median overall survival in the second-line setting. Shares in Revolution have skyrocketed this year on the back of the readouts and regulatory wins for its pancreatic cancer drug. Credit: Revolution Medicines. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The…

Source: Pharmaceutical Technology